尿毒症维持性血液透析并发幽门螺杆菌阴性慢性糜烂性胃炎48例疗效观察

目的 探讨尿毒症维持性血液透析并发幽门螺杆菌阴性慢性糜烂性胃炎的有效治疗方法.方法 对48例尿毒症维持性血液透析并发幽门螺杆菌阴性慢性糜烂性胃炎的患者进行胃镜及胃幽门螺杆菌检查明确诊断.48例患者随机分为2组,治疗组24例给予泮托拉唑40 mg口服,1次/d；配合麦滋林-S颗粒口服,0.67 g/次,3次/d.对照组24例仅同剂量的泮托拉唑治疗；2组疗程均为21 d.比较2组的疗效.结果 尿毒症维持性血液透析患者的上消化道症状重,治疗组治疗21 d后临床症状改善,胃镜下表现及病理组织学等方面均有不同程度的好转,较对照组有显著疗效(治疗组总有效率为95.83％,对照组为83.33％,U=2.716,P＜0.01)；疗程结束后复查胃镜下黏膜病变修复情况,治疗组总有效率83.33％,对照组为45.83％,U=2.349,P＜0.05.结论 泮托拉唑结合麦滋林-S治疗尿毒症维持性血液透析并发幽门螺杆菌阴性慢性糜烂胃炎具有显著疗效.

Clinical study on 48 cases of uremic maintenance hemodialysis patients with helicobacter pylori-negative chronic erosive gastritis

Objective To explore effective treatment of uremic hemodialysis patients with chronic helicobacter pylori-negative erosive gastritis.Methods Fourty-eight cases of uremic hemodialysis patients with helicobacter pylori-negative chronic erosive gastritis were diagnosed by detection of helicobacter pylori and endoscopic examination.Fourty-eight patients were randomly divided into two groups,treatment group (24 patients) with oral pantoprazole 40 mg,once a day,combinding with oral Marzulene-S particles,each 0.67 g,three times a day,the control group (24 cases ) only with the dose of pantoprazole treatment.Effect of treatment was compared in these two groups after treatment for 21 days.Results Twenty-one days after treatment,the clinical symptoms of uremic hemodialysis patients with upper gastrointestinal improved in treatment group,and the performance of endoscopic and histopathological has varying degree of improvement.It shows that pantoprazole combined with Marzulene-S treatment group has a significant effect than that single treatment with pantoprazole group.In the treatment group,the total effective rate was 95.83％,however it was 83.33％ in the control group( U =2.716,P ＜ 0.01 ).Repair of mucosal lesions were significantly different between the two groups ( total effective rate 83.33％ vs 45.83％,U =2.349,P ＜ 0.05 ).Conclusion Pantoprazole combined with Marzulene-S therapy has a significant effect on uremic hemodialysis patients with chronic Helicobacter pylori-negative erosive gastritis.